GlobeNewswire by notified

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity

Share

PRESS RELEASE

July 26, 2021

Tesomet is the first and only investigational treatment for hypothalamic obesity to receive orphan drug designation

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tesomet for the treatment of hypothalamic obesity (HO). Tesomet is the first and only investigational treatment for HO to receive orphan drug designation. Saniona is preparing to initiate two Phase 2b studiesof Tesomet in the second half of this year, one in HO and the other in Prader-Willi syndrome (PWS), for which Tesomet has already received orphan drug status.

“There are currently no FDA-approved medicines for hypothalamic obesity. Despite the devastating weight gain and hunger this rare disease can cause, there has been relatively little drug development specifically for HO. Saniona is proud to be pioneering a regulatory path forward for people living with HO, and we are thrilled to have received the first-ever FDA orphan drug designation in HO. We look forward to initiating our Phase 2b trial of Tesomet for HO in the second half of this year,” said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development at Saniona.

Amy Wood, Executive Director of the Raymond A. Wood Foundation and parent of a child living with hypothalamic obesity, commented, “The recognition of the first orphan drug designation in hypothalamic obesity is a critical milestone for the HO community. HO places a tremendous burden on caregivers and families; it causes severe weight gain and constant hunger no matter how much a person eats, forcing us to lock up food and avoid social situations where food is served. We are incredibly grateful that both the FDA and Saniona recognize the seriousness of this disorder, and we hope this orphan drug designation is the first step towards having an innovative treatment.”

Orphan drug designation is a special status granted by the FDA to medicines and biologics that are intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S. The number of people living with HO is estimated to be between 10,000 and 25,000 in the U.S. and between 16,000 and 40,000 in Europe. Receiving orphan designation qualifies Saniona for certain development benefits, including tax credits, elimination of certain FDA license application fees, and seven years of market exclusivity in the U.S. following approval.

Saniona previously evaluated Tesomet in a 24-week, double-blind, randomized, placebo-controlled initial Phase 2 trial in HO. Adults receiving Tesomet demonstrated statistically significant reductions in body weight and improvements in waist circumference and glycemic control. These improvements were maintained during an additional 24-week open-label extension. Tesomet was reported to be generally well-tolerated, and most adverse events were mild. The most common adverse events included sleep disorders, dizziness, dry mouth and headache. No clinically significant differences in heart rate or blood pressure were observed between the Tesomet-treated patients and the placebo-treated patients.

In preparation for the initiation of the Phase 2b study of Tesomet in HO in the second half of 2021, Saniona has selected the clinical research organization (CRO) that will support the clinical trial and is in the process of assessing and selecting clinical trial sites in the U.S. and globally. Saniona has also selected the contract manufacturer to produce Tesomet for Phase 2b and Phase 3 clinical trials. Additionally, Saniona has initiated multiple partnerships with the HO advocacy community to incorporate caregiver and patient feedback into the clinical trial process and to provide the community with education on clinical trials.

Saniona is also evaluating Tesomet for the treatment of Prader-Willi syndrome (PWS) and plans to begin a Phase 2b trial in this indication in the second half of this year. The FDA granted orphan drug designation to Tesomet for the treatment of PWS in March 2021.

For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com

This information is such information as Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 CEST on 26July 2021.

About Saniona
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona’s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated. Lead candidate SAN711 is in a Phase 1 clinical trial and may be applicable in the treatment of rare neuropathic disorders, and SAN903 for rare inflammatory and fibrotic disorders is advancing through preclinical development. Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and a corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

About Tesomet
Tesomet is an investigational fixed-dose combination therapy of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). Saniona is advancing Tesomet for hypothalamic obesity and Prader-Willi syndrome, two severe rare disorders characterized by obesity and loss of appetite control. The programs are currently in clinical development. Saniona holds worldwide rights to Tesomet and is actively evaluating opportunities to advance this treatment globally.

About Hypothalamic Obesity (HO)
Hypothalamic obesity (HO) is a rare disorder caused by injury to a region of the brain known as the hypothalamus. This injury is most commonly sustained during surgery to remove a noncancerous tumor called a craniopharyngioma (CP). HO is characterized by rapid, excessive, and intractable weight gain that persists despite restricted food intake. Patients may have hyperphagia, an uncontrollable hunger, and may display abnormal food seeking behavior such as stealing food. Additional symptoms may include memory impairment, attention deficit, excessive daytime sleepiness and lethargy, issues with impulse control, and depression. HO patients are also at increased risk of developing obesity-related comorbid conditions such as Type 2 diabetes, non-alcoholic fatty liver disease, hypertension, stroke, and congestive heart failure. Ultimately, CP survivors with extensive hypothalamic injury report a 20-year mortality rate at least three times higher than CP survivors without extensive hypothalamic injury. There are no medications approved specifically for HO, and there is no cure for this disease. Many HO patients are treated with approaches used for general obesity such as surgery, medication and lifestyle counseling, but these are mostly ineffective. The number of patients with of HO is estimated to be between 10,000 and 25,000 in the U.S. and between 16,000 and 40,000 in Europe.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Investeringsforeningen ValueInvest Danmark – Prospektopdatering19.3.2024 14:56:52 CET | pressemeddelelse

Opdateret prospekt for Investeringsforeningen ValueInvest Danmark offentliggøres dags dato. Der er fore­taget følgende opdateringer i prospektet: Justeringer, som reflekterer, at Macquarie Investment Management Europe S.A.s rolle er ændret fra investeringsrådgiver til porteføljeforvalter.Ændring af reference fra bilag 5 i lov om finansiel virksomhed til bilag 2 i lov om fondsmæglerselskaber og investeringsservice og -aktiviteter.Ændring til bilaget vedr. bæredygtighedsrelaterede oplysninger i afsnittet ”Hvilke miljømæssige og/eller sociale karakteristika fremmes af dette finansielle produkt?” Prospektet og dets bilag vedrørende bæredygtighedsrelaterede oplysninger er vedhæftet denne fondsbørsmeddelelse og kan endvidere downloades på www.valueinvest.dk eller rekvireres ved henvendelse til BI Management A/S, Bredgade 40, 1260 København K, tlf. 77 30 90 00. Med venlig hilsen BI Management A/S Martin Fjordlund Smidt Direktør Vedhæftet fil Prospekt IF ValueInvest Danmark 2024.03.19 FINAL cl

Investeringsforeningen ValueInvest Danmark – Årsrapport 202319.3.2024 14:50:20 CET | pressemeddelelse

Bestyrelsen har i dag behandlet og vedtaget årsrapporten 2023 for Investeringsforeningen ValueInvest Danmark (”Foreningen”). Årsrapporten med beretning, regnskab og nøgletal er vedhæftet denne meddelelse og vil endvidere kunne downloades via hjemmesiden www.valueinvest.dk. Årsrapporten vil blive fremlagt til godkendelse på Foreningens ordinære generalforsamling den 19. april 2024. Spørgsmål til årsrapporten kan rettes til Foreningens formand, Ole Steffensen, på tlf. 20 45 82 44. Med venlig hilsen Investeringsforeningen ValueInvest Danmark Ole Steffensen, bestyrelsesformand Jens Harck, næstformand Vedhæftet fil 2023 Årsrapport 2023 - Investeringsforeningen ValueInvest Danmark

Kvika banki hf.: Hugrún Sif Harðardóttir appointed internal auditor of Kvika banki hf.19.3.2024 14:30:57 CET | Press release

Hugrún Sif Harðardóttir has been appointed internal auditor of Kvika banki hf. by the bank's Board of Directors and has commenced her duties. Hugrún has been a valued member of Kvika's internal audit team since last autumn, previously serving as the deputy director of the internal audit department. With approximately 15 years of experience in the financial sector, she brings extensive expertise in internal auditing, operational risk management, and process optimization. Prior to joining Kvika, Hugrún held positions in internal audit at Landsbankinn from 2021 to 2023 and at Arion banki from 2009 to 2021, where she specialized in internal audit, process optimization, and operational risk management. Additionally, she has a background in quality and information security management, having worked at ANZA and Teris. Hugrún holds a Master of Science degree in Analysis, Design, and Management of Information Systems from the London School of Economics and Political Science (LSE), awarded in 20

SCOR Investment Partners reaches EUR 20 billion of asset under management driven by significant net inflows19.3.2024 14:24:11 CET | Press release

PRESS RELEASE | March 19, 2024N° 01- 2024 SCOR Investment Partners reaches EUR 20 billion of asset under management driven by significant net inflows. SCOR Investment Partners, the SCOR Group’s asset management company, is proud to announce that it has surpassed the milestone of EUR 20 billion of assets under management. 2023 provided a turning point for third-party activities with a significant acceleration of assets under management. This growth is the result of the strategic objectives pursued by SCOR Investment Partners, which offers specialized investment solutions to institutional clients, and is in line with the SCOR group's latest strategic plan, Forward 2026. As of end 2023, third-party assets under management reached almost EUR 7.4 billion driven by close to EUR 900 million net inflows from external investors. Louis Bourrousse, Chief Executive Officer of SCOR Investment Partners, comments:“We are thrilled of these results confirming that we are recognized by our clients. Thes

HiddenA line styled icon from Orion Icon Library.Eye